Cytiva Acquires Intermountain Life Sciences
The acquisition of Intermountain Life Sciences will double Cytiva’s capacity for buffers and liquid cell culture media at its manufacturing site in Logan, Utah.
On June 29, 2021, Cytiva announced that it has acquired Intermountain Life Sciences, a manufacturer of high-purity water, buffers, and liquid cell culture media. Through the acquisition, Cytiva will use Intermountain’s manufacturing site in Logan, Utah to rapidly boost its liquid cell culture production by millions of liters.
Intermountain’s Logan site is fully functional and running efficiently, and Cytiva intends to build on that momentum to ramp up production through hiring. The site and its capabilities will become part of Cytiva’s cell culture media portfolio.
“The demand for buffers and cell culture media has grown substantially in recent years thanks to their use in gene therapies, as well as their use in making COVID-19 vaccines and therapies. Adding the capacity and talent from Intermountain Life Sciences will allow us to accelerate deliveries to our customers,” said Olivier Loeillot, vice-president, Cytiva, in a company press release. “We’re really impressed with the quality practices that we see, and we’ll be bringing dozens of people on board to build on the work already being done at the site.”
“At Intermountain, we aim to be an innovative, responsive, and quality-driven outsourcing partner to the biotechnology industry. As part of Cytiva, we’ll continue on this mission at a larger scale,” said Russ Wilcox, president of Intermountain, in the press release.
Source: Cytiva
